title: A novel nano-carrier transdermal gel against inflammation.
abstract: The objective was to develop a stable, reproducible and patient non-infringing novel transdermal drug delivery system "nano-carrier transdermal gel" (NCTG) in combination of partial dose replacement of diclofenac diethylamine (DDEA) by curcumin (CRM). The drug content of gel was 99.30 and 97.57% for DDEA and CRM. Plasma samples were analyzed by liquid chromatography with triple-quadrupole tandem mass spectrometer (LC-MS/MS). Data were integrated with Analyst™ and analyzed by WinNonlin; stability parameters were analyzed using Tukey-Kramer multiple comparison test. Its average skin irritation scored 0.49 concluded to be non-irritant, safe for human use and in vivo studies revealed significantly greater extent of absorption and highly significant inhibition (%) of carrageenan induced paw edema. The results also demonstrated that encapsulation of drugs in nano-carrier increases its biological activity due to superior skin penetration potential. Hence, a novel once day transdermal gel of nano-carrier (nano-transfersomes; deformable vesicular) is achieved, to increase systemic availability, subsequent reduction in dose and toxicity of DDEA was developed for the treatment of inflammation.
authors.affiliation: P.D.M. College of Pharmacy, Bahadurgarh, India.
authors.forename: Hema
authors.initials: H
authors.lastname: Chaudhary
authors.affiliation: Faculty of Pharmacy, Jamia Hamdard, New Delhi, India. Electronic address: hema.manan@gmail.com.
authors.forename: Kanchan
authors.initials: K
authors.lastname: Kohli
authors.affiliation: P.D.M. College of Pharmacy, Bahadurgarh, India.
authors.forename: Vikash
authors.initials: V
authors.lastname: Kumar
mesh_terms: D000179:Acrylates / Q000737:chemistry; D000279:Administration, Cutaneous; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity; D001682:Biological Availability; D002351:Carrageenan; D002626:Chemistry, Pharmaceutical; D002853:Chromatography, Liquid; D003474:Curcumin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity; D004008:Diclofenac / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004337:Drug Carriers; D004338:Drug Combinations; D004355:Drug Stability; D005782:Gels; D007249:Inflammation / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D053758:Nanoparticles; D036103:Nanotechnology; D017208:Rats, Wistar; D012867:Skin / Q000187:drug effects / Q000473:pathology; D023422:Skin Irritancy Tests; D053719:Tandem Mass Spectrometry; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D000179:Acrylates; D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D004338:Drug Combinations; D005782:Gels; D004008:Diclofenac; D002351:Carrageenan; D003474:Curcumin; C453622:carbopol 934P
keywords: Drug delivery; Nano-carrier; Nano-transfersomes; Stability; Toxicity; Transdermal gel